🔎 Trials Near Me

Home › Chronic-Phase Myeloid Leukemia › New York

Chronic-Phase Myeloid Leukemia clinical trials in New York

5 studies for Chronic-Phase Myeloid Leukemia are looking for participants at sites in New York.

Cities in New York

Study of Olverembatinib (HQP1351) in Patients With CML-CP

  • Ascentage Investigative Site #1068, Rochester
  • Ascentage Investigative Site #1053, Shirley
  • Ascentage Investigative Site #1160, Stony Brook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06423911

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT04838041

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

  • NY Cancer and Blood Specialists, East Setauket
  • SUNY Upstate Medical University, Syracuse
RecruitingObservational study
Ages 18 to 100 · All sexes · Updated Jul 20, 2026 · NCT07091019

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

  • Memorial Sloan Kettering Cancer Center, New York
  • Montefiore Medical Center, The Bronx
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 1, 2026 · NCT05304377

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

  • Memorial Sloan Kettering Cancer Center - Main Campus, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jan 12, 2026 · NCT06163430

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.